No connection

Search Results

AVTR vs LLY

AVTR
Avantor, Inc.
BEARISH
Price
$11.80
Market Cap
$8.05B
Sector
Healthcare
AI Confidence
85%
LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AVTR
--
LLY
41.7
Forward P/E
AVTR
12.97
LLY
22.78
P/B Ratio
AVTR
1.44
LLY
32.33
P/S Ratio
AVTR
1.22
LLY
13.16
EV/EBITDA
AVTR
10.78
LLY
27.08

Profitability

Gross Margin
AVTR
33.13%
LLY
83.04%
Operating Margin
AVTR
8.48%
LLY
44.9%
Profit Margin
AVTR
-1.25%
LLY
31.67%
ROE
AVTR
-1.48%
LLY
101.16%
ROA
AVTR
3.43%
LLY
19.41%

Growth

Revenue Growth
AVTR
-5.3%
LLY
42.6%
Earnings Growth
AVTR
--
LLY
51.4%

Financial Health

Debt/Equity
AVTR
0.69
LLY
1.65
Current Ratio
AVTR
1.49
LLY
1.58
Quick Ratio
AVTR
0.88
LLY
0.78

Dividends

Dividend Yield
AVTR
--
LLY
0.68%
Payout Ratio
AVTR
0.0%
LLY
26.14%

AI Verdict

AVTR BEARISH

The Advanced Deterministic Scorecard reveals significant financial weakness with a Piotroski F-Score of just 2/9, indicating poor profitability, deteriorating margins, and weak operating performance. Despite a reasonable Debt/Equity ratio and positive operating cash flow proxies, the company is unprofitable on a net basis (negative net margin and ROE), with declining revenue and earnings. Insider selling, a bearish technical trend, and a sharp multi-year price decline further reinforce deterioration in fundamentals. Although the forward P/E of 12.97 appears low, weak execution, shrinking profits, and lack of intrinsic value benchmarks suggest the market is pricing in continued challenges.

Strengths
Forward P/E of 12.97 suggests potential undervaluation relative to sector average P/E of 202.93
Operating margin remains healthy at 8.48%, indicating pricing power or cost control at operational level
Debt/Equity ratio of 0.69 is below sector average of 2.31, suggesting conservative capital structure
Risks
Piotroski F-Score of 2/9 signals severe financial distress and high risk of continued underperformance
Negative net profit margin (-1.25%) and negative ROE (-1.48%) indicate systemic profitability issues
Revenue declining YoY by 5.30% and EPS down 15.4% YoY point to deteriorating fundamentals
LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

AVTR vs LLY: Head-to-Head Comparison

This page compares Avantor, Inc. (AVTR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile